611 related articles for article (PubMed ID: 18547126)
1. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease.
Gallagher DA; Schrag A
CNS Drugs; 2008; 22(7):563-86. PubMed ID: 18547126
[TBL] [Abstract][Full Text] [Related]
2. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Jankovic J; Stacy M
CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
[TBL] [Abstract][Full Text] [Related]
3. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
Deane KH; Spieker S; Clarke CE
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004553. PubMed ID: 15495118
[TBL] [Abstract][Full Text] [Related]
4. New pharmacotherapy for Parkinson's disease.
Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
[TBL] [Abstract][Full Text] [Related]
5. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
Deleu D; Northway MG; Hanssens Y
Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
Nyholm D
Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson's Disease: a Network Meta-Analysis.
Li BD; Cui JJ; Song J; Qi C; Ma PF; Wang YR; Bai J
Cell Physiol Biochem; 2018; 45(1):119-130. PubMed ID: 29339630
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
Kulisevsky J; Pagonabarraga J
Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
[TBL] [Abstract][Full Text] [Related]
10. Parkinson's Disease: From Pathogenesis to Pharmacogenomics.
Cacabelos R
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273839
[TBL] [Abstract][Full Text] [Related]
11. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.
Sanford M; Scott LJ
CNS Drugs; 2011 Aug; 25(8):699-719. PubMed ID: 21790211
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
13. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.
Fox SH; Katzenschlager R; Lim SY; Ravina B; Seppi K; Coelho M; Poewe W; Rascol O; Goetz CG; Sampaio C
Mov Disord; 2011 Oct; 26 Suppl 3():S2-41. PubMed ID: 22021173
[TBL] [Abstract][Full Text] [Related]
14. Milestones in Parkinson's disease therapeutics.
Rascol O; Lozano A; Stern M; Poewe W
Mov Disord; 2011 May; 26(6):1072-82. PubMed ID: 21626552
[TBL] [Abstract][Full Text] [Related]
15. Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease.
Gencler OS; Oztekin N; Oztekin MF
Ideggyogy Sz; 2022 Jan; 75(1-02):39-49. PubMed ID: 35112520
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of pramipexole on quality of life in patients with Parkinson's disease: a systematic review and meta-analysis.
Li T; Zou S; Zhang Z; Liu M; Liang Z
BMC Neurol; 2022 Aug; 22(1):320. PubMed ID: 36008796
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
Binde CD; Tvete IF; Gåsemyr JI; Natvig B; Klemp M
Eur J Clin Pharmacol; 2020 Dec; 76(12):1731-1743. PubMed ID: 32710141
[TBL] [Abstract][Full Text] [Related]
18. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Najib J
Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
[TBL] [Abstract][Full Text] [Related]
19. Ropinirole: a review of its use in the management of Parkinson's disease.
Matheson AJ; Spencer CM
Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
[TBL] [Abstract][Full Text] [Related]
20. Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson's Disease.
Martinez-Martin P; Rodriguez-Blazquez C; Forjaz MJ; Kurtis MM
CNS Drugs; 2015 May; 29(5):397-413. PubMed ID: 25968563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
